An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM)
Part of paid clinical trials in Miami, Florida.
- Sponsor
- Affinia Therapeutics
- Study ID
- NCT07426419
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- BAG3 Mutation Associated Dilated Cardiomyopathy
- Dilated Cardiomyopathy (DCM)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Not accepted
Interventions
- AFTX-201 — GENETICAFTX-201 is a gene therapy product consisting of the ATC-0187 capsid containing the BCL2-associated Athanogene 3 (BAG3) transgene. It is administered as a single intravenous infusion
Study Details
This is a Phase 1/2, open-label, dose-exploration and dose-expansion, clinical trial evaluating the safety, tolerability, pharmacodynamics, and preliminary efficacy of a single intravenous infusion of AFTX-201 in adults with dilated cardiomyopathy caused by a BAG3 gene mutation
Key Dates
- First listed
- Feb 23, 2026
- Start date
- Jun 30, 2026
- Status verified
- Jul 2026
- Primary completion
- Dec 31, 2028
- Completion
- Dec 31, 2032
Study Design
- Enrollment
- 22 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: AFTX-201Participants will receive a single intravenous dose of AFTX-201
Primary Outcome Measure
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) [ Time Frame: Baseline through 12 months ]
Central Contacts
- Clinical Trials Information(617) 430-7817
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Miami Hospital and Clinics | Miami | Florida | 33136 | |
| St. Lukes Hospital | Kansas City | Missouri | 64111 | |
| Houston Methodist Hospital | Houston | Texas | 77030 |
Find similar trials in Miami, FL
Related Studies
- ALXN2350 in Adult Participants With BAG3-Associated Dilated CardiomyopathyPHASE1/PHASE2 · Recruiting · Alexion Pharmaceuticals, Inc. · Birmingham, Alabama
- Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac ArrhythmiasEnrolling By Invitation · Johns Hopkins University · Baltimore, Maryland
- A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated CardiomyopathyPHASE1 · Recruiting · Rocket Pharmaceuticals Inc. · San Diego, California
- UIC Multi-Ethnic DCM RegistryRecruiting · University of Illinois at Chicago · Chicago, Illinois